TWYNSTA TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

TELMISARTAN; AMLODIPINE (AMLODIPINE BESYLATE)

Pieejams no:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

ATĶ kods:

C09DB04

SNN (starptautisko nepatentēto nosaukumu):

TELMISARTAN AND AMLODIPINE

Deva:

40MG; 5MG

Zāļu forma:

TABLET

Kompozīcija:

TELMISARTAN 40MG; AMLODIPINE (AMLODIPINE BESYLATE) 5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

14/28

Receptes veids:

Prescription

Ārstniecības joma:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0252947001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2011-08-03

Produkta apraksts

_ _
_Product Monograph _
_ _
_TWYNSTA (telmisartan/amlodipine) _
_Page 1 of 54 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TWYNSTA
®
Telmisartan / Amlodipine (as Amlodipine Besylate) Tablets
Tablet, 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg, Oral
Angiotensin II AT1 Receptor Blocker / Calcium Channel Blocker
Boehringer Ingelheim (Canada) Ltd.
5180 South Service Road
Burlington, Ontario
L7L 5H4
Date of Initial Authorization:
AUG 11, 2011
Date of Revision:
October 4, 2022
Submission Control Number: 264045
BICL CCDS# 0275-08
Twynsta
®
is a registered trademark used under license by Boehringer Ingelheim
(Canada) Ltd.
_ _
_Product Monograph _
_ _
_TWYNSTA (telmisartan/amlodipine) _
_Page 2 of 54 _
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION
10/2022
7 WARNINGS AND PRECAUTIONS
10/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment.......